DDInter1594 DDInter1676
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Rilonacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Rilonacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dactinomycin
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rilonacept {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Rilonacept {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Rilonacept may lead to a major life threatening interaction when taken with Fingolimod
Rilonacept may lead to a major life threatening interaction when taken with Leflunomide